- Sarepta reported preliminary fourth-quarter net product revenues of $638.2 million.
- The company maintains its 2025 net product revenue projection at between $2.9 billion and $3.1 billion.
- Preliminary net product revenue for Elevidys reached $384.2 million in the fourth quarter.
- The RNA-Based PMO segment reported preliminary net product revenue of $254 million in the fourth quarter.
- As of December 31, 2024, Sarepta had cash, cash equivalents, restricted cash, and investments totaling approximately $1.5 billion.
- Analyst consensus shows strong confidence in Sarepta with 20 buy ratings, 0 hold, and 1 sell.
“`
A look at Sarepta Therapeutics Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Smartkarma’s Smart Scores paint a promising picture for Sarepta Therapeutics, a biopharmaceutical company dedicated to advancing RNA-based therapeutics for rare and infectious diseases. With a strong emphasis on growth and momentum, Sarepta received above-average scores in these critical areas. Its focus on innovation and development positions the company well for long-term success.
While Sarepta’s value and dividend scores may not be as high as its growth and momentum ratings, its resilience score demonstrates a solid foundation. The company’s ability to adapt to challenges and maintain stability further reinforces its potential for sustained growth. Overall, Sarepta Therapeutics shines in key areas that are vital for its continued success in the competitive biopharmaceutical landscape.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
